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Clinical Practice Points. Plasmablastic lymphoma (PBL) is a rare and highly aggressive variant of diffuse large B cell lymphoma
with median survival of advanced stage patients varying between 6 and 15 months in previous reports. We report here a human
immunodeficiency virus-infected patient surviving over 12 years following treatment for advanced PBLwith EPOCHchemotherapy
and intrathecal therapy. This case highlights the potential for improved survival in PBL with intensive chemotherapy. Further,
literature review suggests promising prospects utilizing novel targeted therapies to increase the rate of prolonged responses.
1. Introduction
First identified in 1997, plasmablastic lymphoma (PBL) was
initially described as an aggressive lymphoma occurring
mainly in the oral cavity of HIV-infected patients [1]. Despite
the lack of CD20 expression and the presence of CD79a
in association with the plasma cell markers MUM1 and
CD138, genomic analysis indicated that PBL is a variant of
diffuse large B cell lymphoma (DLBCL) originating from a
postgerminal B cell [1–3]. Later reports found that PBL also
occurs in non-HIV patients and can manifest in extraoral
sites in both groups [4–6].
The prognosis of HIV+ PBL patients receiving the usual
treatment for DLBCL has been extremely poor with median
overall survival of 15 months [1, 6–8]. Here we present an
HIV+ PBL patient with an ongoing progression free survival
of 149 months.
2. Case Report
This 49-year-old man was diagnosed with HIV in 2001
and was receiving antiretroviral therapy. His CD4 count
was 146 cells/𝜇L when he was hospitalized in August 2004
with symptoms of headache, difficulty swallowing, and a 30-
pound weight loss over a 4-week period. Physical findings
included ophthalmoparesis, bilateral lid droop, and evidence
for 3rd, 4th, and 6th cranial nerve palsies. CT and MRI
scans demonstrated a large nasopharyngeal mass eroding
the skull base and clivus, invading the sphenoid sinus, the
pituitary sella, and cavernous sinuses, and enveloping the
cranial nerves and carotid arteries. Biopsy revealed large
CD20-negative atypical cells with brisk mitotic activity with
some cells appearing plasmacytoid (Figure 1).The tumor was
positive for CD138, CD30, EBER, and LCA and in rare cells
CD79a and confirmed to be negative for CD20, CD43, CD56,
and CD3, consistent with the diagnosis of PBL (courtesy
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Figure 1: Diffuse lymphoid infiltrates consisting of predominantly large atypical cells with plasmacytic differentiation ((a), H&E, 400x).
Immunohistochemistry stains revealed that the tumor is positive for CD138 (d) but negative for CD3 (b) and CD20 (c).
of Dr. Elaine Jaffe, National Institutes of Health). Cere-
brospinal fluid also demonstrated lymphomatous involve-
ment. There were no other areas of lymphoma involvement.
International Prognostic Index score was 4, indicating high
risk.
Palliative radiation up to 1500 cGy targeting the nasopha-
ryngeal mass was given because of distressing respiratory
and swallowing symptoms but was interrupted to begin
chemotherapy with DA-EPOCH (dose-adjusted infusional
etoposide, vincristine, doxorubicin, cyclophosphamide, and
prednisone) [9] along with combination antiretroviral ther-
apy. He received intrathecal methotrexate, hydrocortisone,
and liposomal cytarabine via lumbar puncture and Ommaya
reservoir. After the first cycle of DA-EPOCH reduction in the
mass was noted on CT scan, and a PET scan showed no FDG
uptake. He received a total of 6 cycles; a stable necrotic mass
was noted from the 4th to the 6th cycle. He required active
supportive care and gradually regained full functionality over
the next 6 months, including almost full recovery of extraoc-
ular movement. He continues to require replacement therapy
for panhypopituitary function. He remains on antiretroviral
therapy with CD4 counts ranging from 129/𝜇L to 365/𝜇L. To
date, he has remained free of recurrence of PBL for over 12
years.
3. Discussion
The prognosis of plasmablastic lymphoma remains poor
despite the use of combination antiretroviral therapy unlike
other HIV-related lymphomas [6, 10–13]. The prospective
German cohort study of 292 AIDS-related lymphoma iden-
tified 34 patients with PBL between 2005 and 2012 who
were found to have a 2-year survival of 43% as compared to
63% of the DLBCL patients despite similar median CD4 cell
concentrations (200 cells/𝜇L) and similar IPI score risk status
[12]. The main cause of death was lymphoma progression.
Castillo et al. reported a retrospective study from 13American
institutions of 50 consecutively diagnosed and treated HIV+
PBL between 2000 and 2010 which found a median overall
survival (OS) of 11 months with no apparent difference
between those treated with CHOP or those receiving more
intensive medications [7]. Two other studies of 61 and 135
patients including both HIV+ and negative patients also
found no significant difference with the use of intensive
regimens as compared to CHOP [13, 14].
Alternatively, a study of 19 Stage III or IV HIV+ PBL
disease showed a survival benefit with DA-EPOCH treat-
ment as compared to CHOP (17 months versus 7 months,
𝑝 = 0.014) [15]. The National Comprehensive Cancer Net-
work currently recommends more intensive chemotherapy
than CHOP, including CODOX-M/IVAC (modified), DA-
EPOCH, andHyperCVAD [16] although Loghavi et al. found
CHOP-treated patients tended to show better OS than those
treated with HyperCVAD (𝑝 = 0.078) [13]. There have been
no previous prospective trials of therapy of PBL due to its
rarity.Theongoing prospective trials ofDA-EPOCH for high-
risk DLBCL by the Clinical Trials Support Unit (CTSU) 9177
and NCT01092182 will include PBL.
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Although the percentage of complete remissions to
chemotherapy in HIV+ PBL is high, ranging from 50% to
65%, early relapses have accounted for the poor OS which
correlate with IPI scores rather thanAIDS prognostic criteria;
survival rate at 5 years has been estimated at 25% with
some Stages 3 and 4 patients noted in survival curves up to
approximately 70 months [7, 8, 13, 14]. Our patient represents
one of the most long-lived members of small subset of
patients whose tumors are sensitive to chemotherapy despite
advanced disease. The role that the palliative radiotherapy
played in his remission is not clear. Consolidative radiation
postintensive doxorubicin chemotherapy has been reported
from a single institution to give excellent responses in Stages
I and II PBL with OS responses at 42 months in 7 patients, 2
of whom were HIV+ [17].
Investigations of the biologic features of PBL with its
similarities to activatedB cell (ABC) lymphoma andmyeloma
have prompted the possibility that therapies for these cancers
may increase the number of patients who can achieve durable
remissions. The poorer outcome of the ABC subtype of
DLBCL as compared to the germinal center B cell (GBC)
subtype has been attributed to its overexpression of the NF-
kB pathway that promotes proliferation and survival [18,
19]. The addition of bortezomib, an inhibitor of the NF-
𝜅B pathway, to EPOCH improved responses and survival
in ABC-DLBCL supporting the hypothesis that the NF-𝜅B
pathway is playing a key role in tumor growth and survival
[20]. Extrapolating this concept to PBL are 2 reports showing
that the combination of bortezomib DA-EPOCH achieved
durable complete responses in 2 HIV-positive and 2 HIV
negative patients with survival times of 12–24months [21, 22].
Expression of CD30, found in about 50% of PBL tumors,
provides a rationale for the utilization of themonoclonal anti-
body immunoconjugate brentuximab vedotin. Two refrac-
tory HIV negative PBL patients showed marked shrinkage of
tumor however with fatal outcomes due to rapid tumor lysis
following brentuximab vedotin alone or with lenalidomide
[23, 24]. Another potential novel immunoconjugate therapy
is BT-062 which targets CD138 and is being tested inmultiple
myeloma [25].
Small case series and bonemarrow registry data have also
shown that autologous hematopoietic stem cell transplan-
tation (auto-SCT) for HIV-positive and HIV negative PBL
when used particularly following first complete remission
is feasible and may provide long progressive-free survival
[26, 27]. Cattaneo et al. reported registry data which showed
a 30% relapse rate (solely within the first 4 months) and OS
of 58% at 2 years for 24 patients who underwent auto-SCT
in first complete or partial remission between 2001 and 2011
[27].
There are promising future directions to consider in
the treatment of PBL. Chen et al. reported upregulation
of the programmed cell death ligand 1 (PD-L1) in 4 of 9
plasmablastic lymphoma biopsies offering the potential of
the new therapies targeting the PD-L1 pathway to prolong
survival [28].
In conclusion, our patient’s prolonged relapse-free
course following EPOCH and antiretroviral therapy suggests
that even HIV patients with advanced stage plasmablastic
lymphoma may have prolonged survival equivalent to cure.
Future studies with targeted therapies have the potential
to make long-term durable responses possible for a greater
number of patients.
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